In the OCI-AML3 and THP1 AML models, significant tumor growth inhibition was observed for the anti-SAIL ADCs compared with the nontargeting isotype control ADC at a dose level of 3 mg/kg (Figure 6a and b). The gene discussed is C16orf54; the disease is acute myeloid leukemia.